Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Verax Biomedical's Platelet PGD test

This article was originally published in The Gray Sheet

Executive Summary

First rapid test for the detection of bacterial contamination in pooled platelets derived from whole blood gains FDA market go-ahead Nov. 13. Bacterial contamination of platelets "is the leading infectious cause of patient fatalities associated with platelet transfusions," according to Karen Midthun, M.D., acting director of FDA's Center for Biologics Evaluation and Research. "A rapid test for pooled platelets is an important step in improving safety for patients who are transfused with platelets," Midthun said. The test uses a single-use strip to indicate the presence of bacteria in less than 60 minutes. Clinical studies showed that the test "improved the sensitivity for detecting bacterial levels by 100- to 1,000-fold over existing methods used to test pooled platelets prior to transfusion," FDA says. Fenwal is the exclusive global distributor of the test, which was developed by Verax

You may also be interested in...



Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.

FDA Wants To Put Hep C Tests On 510(k) Pathway

The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.

Topics

UsernamePublicRestriction

Register

MT028208

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel